Weiss Ratings Reaffirms Sell (D+) Rating for USANA Health Sciences (NYSE:USNA)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D+)" rating for USANA Health Sciences, indicating analysts are not optimistic about the stock's performance.
• USANA's stock has a current consensus rating of "Reduce" with an average target price of $36.00, after a downgrade from Zacks Research.
• Despite positive quarterly earnings results, USANA's stock has traded recently at around $26.54, significantly below its 52-week high of $41.83.

USANA Health Sciences (NYSE:USNA - Get Free Report)'s stock had its "sell (d+)" rating reaffirmed by stock analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Separately, Zacks Research cut shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Reduce" and an average target price of $36.00.

USANA Health Sciences Stock Performance

USANA Health Sciences stock traded up $0.21 during trading on Wednesday, reaching $26.54. 73,859 shares of the company's stock were exchanged, compared to its average volume of 168,663. The company's 50-day moving average is $29.93 and its two-hundred day moving average is $29.36. USANA Health Sciences has a 52-week low of $23.10 and a 52-week high of $41.83. The firm has a market cap of $484.79 million, a price-to-earnings ratio of 14.72, a PEG ratio of 0.85 and a beta of 0.61.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, topping analysts' consensus estimates of $0.54 by $0.20. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. The firm had revenue of $235.85 million during the quarter, compared to analysts' expectations of $225.20 million. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. Analysts anticipate that USANA Health Sciences will post 2.45 EPS for the current year.

Insider Transactions at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 1,058 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $29.10, for a total transaction of $30,787.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Mulham Mulham sold 3,515 shares of the firm's stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the transaction, the insider directly owned 9,260 shares in the company, valued at $280,207.60. This represents a 27.51% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.63% of the company's stock.

Hedge Funds Weigh In On USANA Health Sciences

A number of large investors have recently bought and sold shares of the business. Pzena Investment Management LLC lifted its holdings in USANA Health Sciences by 9.4% in the second quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company's stock worth $36,583,000 after acquiring an additional 103,074 shares during the last quarter. American Century Companies Inc. lifted its holdings in USANA Health Sciences by 9.2% in the first quarter. American Century Companies Inc. now owns 255,242 shares of the company's stock worth $6,884,000 after acquiring an additional 21,445 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of USANA Health Sciences by 46.2% in the first quarter. Jacobs Levy Equity Management Inc. now owns 188,511 shares of the company's stock valued at $5,084,000 after purchasing an additional 59,535 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of USANA Health Sciences by 23.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 173,997 shares of the company's stock valued at $4,693,000 after purchasing an additional 33,141 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in shares of USANA Health Sciences by 64.6% in the second quarter. Ameriprise Financial Inc. now owns 150,090 shares of the company's stock valued at $4,582,000 after purchasing an additional 58,921 shares during the period. Institutional investors own 54.25% of the company's stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.